Mirum Pharmaceuticals, Inc.

DB:08D Stock Report

Market Cap: €1.9b

Mirum Pharmaceuticals Valuation

Is 08D undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 08D when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 08D (€38.8) is trading below our estimate of fair value (€273.59)

Significantly Below Fair Value: 08D is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 08D?

Key metric: As 08D is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 08D. This is calculated by dividing 08D's market cap by their current revenue.
What is 08D's PS Ratio?
PS Ratio6.5x
SalesUS$307.03m
Market CapUS$1.97b

Price to Sales Ratio vs Peers

How does 08D's PS Ratio compare to its peers?

The above table shows the PS ratio for 08D vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9.4x
BIO3 Biotest
1.4x3.6%€1.3b
FYB Formycon
14.9x32.0%€905.8m
2INV 2invest
8.7xn/a€67.3m
HPHA Heidelberg Pharma
12.5x16.6%€105.8m
08D Mirum Pharmaceuticals
6.5x24.2%€2.0b

Price-To-Sales vs Peers: 08D is good value based on its Price-To-Sales Ratio (6.5x) compared to the peer average (9.4x).

Price to Sales Ratio vs Industry

How does 08D's PS Ratio compare vs other companies in the DE Biotechs Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIO3 Biotest
1.4x3.6%US$1.39b
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
PA8 Paion
0.2x30.2%US$2.78m
08D 6.5xIndustry Avg. 8.2xNo. of Companies7PS0612182430+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 08D is good value based on its Price-To-Sales Ratio (6.5x) compared to the European Biotechs industry average (8.1x).

Price to Sales Ratio vs Fair Ratio

What is 08D's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

08D PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio6.5x
Fair PS Ratio5.3x

Price-To-Sales vs Fair Ratio: 08D is expensive based on its Price-To-Sales Ratio (6.5x) compared to the estimated Fair Price-To-Sales Ratio (5.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 08D forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€38.80
€59.54
+53.4%
13.2%€69.93€47.25n/a11
Dec ’25€43.00
€59.03
+37.3%
12.6%€68.90€47.19n/a11
Nov ’25€36.00
€54.91
+52.5%
17.2%€65.57€36.02n/a11
Oct ’25€34.80
€54.31
+56.1%
17.6%€65.05€35.73n/a11
Sep ’25€37.40
€54.31
+45.2%
17.6%€65.05€35.73n/a11
Aug ’25€37.00
€52.82
+42.8%
19.7%€65.59€36.03n/a11
Jul ’25€31.40
€53.29
+69.7%
19.6%€66.28€36.41n/a11
Jun ’25€22.40
€44.36
+98.0%
22.2%€60.99€28.65n/a11
May ’25€23.00
€46.05
+100.2%
24.9%€67.79€31.07n/a11
Apr ’25€23.00
€45.08
+96.0%
26.0%€66.25€30.36n/a10
Mar ’25€26.20
€43.56
+66.2%
25.3%€63.67€30.45n/a10
Feb ’25€24.00
€44.31
+84.6%
25.6%€58.96€30.40n/a10
Jan ’25€27.60
€44.24
+60.3%
25.4%€58.62€30.23n/a10
Dec ’24€29.20
€49.98
+71.2%
25.5%€71.28€33.81€43.0010
Nov ’24€25.40
€54.12
+113.1%
22.7%€72.21€35.64€36.007
Oct ’24€29.60
€55.54
+87.6%
29.9%€78.80€32.83€34.805
Sep ’24€24.20
€51.95
+114.7%
33.3%€77.24€32.18€37.404
Aug ’24€23.20
€51.29
+121.1%
31.9%€74.77€31.91€37.004
Jul ’24€22.40
€49.72
+122.0%
33.5%€73.99€31.06€31.407
Jun ’24€24.40
€46.50
+90.6%
36.7%€73.31€27.15€22.408
May ’24€23.20
€46.50
+100.4%
36.7%€73.31€27.15€23.008
Apr ’24€20.80
€48.52
+133.3%
37.3%€78.00€28.19€23.008
Mar ’24€21.80
€48.54
+122.7%
37.4%€78.61€28.07€26.208
Feb ’24€21.20
€49.26
+132.4%
37.9%€78.25€27.95€24.008
Jan ’24€17.80
€51.50
+189.3%
36.9%€82.78€28.22€27.608
Dec ’23€17.60
€53.66
+204.9%
36.7%€84.52€28.81€29.208

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 13:54
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mirum Pharmaceuticals, Inc. is covered by 14 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Joshua SchimmerCantor Fitzgerald & Co.
David LebowitzCitigroup Inc